Clinical Trial Update: A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study evaluating MEDI-573 for safety, tolerability, and antitumor activity in advanced solid tumors; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• MEDI-573

Snippet

Sponsor: MedImmune LLC | Conditions: Cancer | Phase 1 | Status: COMPLETED | Results posted: 2019-03-04